Bruno Figadere

Dr. Bruno Figadere

Laboratories of Natural Substances Chemistry (Pharmacognosy), UMR 8076-BioCIS, Faculty of Pharmacy, University Paris-Sud, France
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2015 in Natural Product Reports
Verified
Journal Article
Open access
PDF file
JLJulien Legros
Julien Legros
BFBruno Figadere
Bruno Figadere
Iron complexes can be used in catalytic or stoichiometric quantities to form C–C bonds for building the backbone of complex molecules. A review of their use in the total synthesis of natural products or pharmacologically important compounds is presented.

2 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Philippe LoiseauPhilippe Loiseau
Philippe Loiseau
BKBalaraman Kaluvu
Balaraman Kaluvu
GBGillian Barratt
Gillian Barratt
SPSébastien Pomel
Sébastien Pomel
RDRémy Durand
Rémy Durand
BFBruno Figadere
Bruno Figadere
There is a need for new, cost-effective drugs to treat leishmaniasis. A strategy based on traditional medicine practiced in Bolivia led to the discovery of the 2-substituted quinoline series as a source of molecules with antileishmanial activity and low toxicity. This review documents the development of the series from the first isolated natural compounds through several hundred synthetized molecules to an optimized compound exhibiting an in vitro IC50 value of 0.2 µM against Leishmania donovani, and a selectivity index value of 187, together with in vivo activity on the L. donovani/hamster model. Attempts to establish structure–activity relationships are described, as well as studies that have attempted to determine the mechanism of action. For the latter, it appears that molecules of this series act on multiple targets, possibly including the immune system, which could explain the observed lack of drug resistance after in vitro drug pressure. We also show how nanotechnology strategies could valorize these drugs through adapted formulations and how a mechanistic targeting approach could generate new compounds with increased activity.

5 July 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GDGael Le Douaron
Gael Le Douaron
LFLaurent Ferrié
Laurent Ferrié
JSJulia E. Sepulveda-Diaz
Julia E. Sepulveda-Diaz
MAMajid Amar
Majid Amar
AHAbha Harfouche
Abha Harfouche
BFBruno Figadere
Bruno Figadere

16 February 2021 in Organic Letters
Verified
Journal Article
Closed access
MLMaría Martín López
María Martín López
NJNicolas Jamey
Nicolas Jamey
APAlexis Pinet
Alexis Pinet
BFBruno Figadere
Bruno Figadere
FLFERRIÉ Laurent
FERRIÉ Laurent

1 January 2002 in Synthetic Communications
Verified
Journal Article
Closed access
MFMohamed A. Fakhfakh
Mohamed A. Fakhfakh
XFXavier Franck
Xavier Franck
AFAlian Fournet
Alian Fournet
RHReynald Hocquemiller
Reynald Hocquemiller
BFBruno Figadere
Bruno Figadere

11 June 2019 in Organic Letters
Verified
Journal Article
Closed access
APAlexis Pinet
Alexis Pinet
TNThuy Linh Nguyen
Thuy Linh Nguyen
GBGuillaume Bernadat
Guillaume Bernadat
BFBruno Figadere
Bruno Figadere
FLFERRIÉ Laurent
FERRIÉ Laurent